BioSpace News Archive

Access Vascular, Inc. announced that it raised a Series C round worth $22 million from a consortium of new and existing investors.

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a conference call and live audio webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET, to review its corporate and financial results for the third quarter of 2023.

Danaher Corporation (NYSE: DHR) (“Danaher” or the “Company”), a leading global life sciences and diagnostics innovator, today announced that Christopher Riley has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Biotechnology business, effective January 1, 2024.

Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today reported financial results and business updates for the quarter ended September 30, 2023.

Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2023, covering the three- and nine-month fiscal periods ended September 30, 2023.

SciSparc Ltd. announced its had been received notice of acceptance for its patent application for Combination of Opioids and N-Acylethanolamines for pain treatment.

Mainz Biomed NV announced positive interim results from its CRC screening campaign through its BGM partnership with Zöller-Kipper GmbH, part of the Zöller group with more than 2,600 employees.

INmune Bio, Inc. announced an update regarding the company’s patent covering its proprietary cell line, “INB16”.

Intra-Cellular Therapies, Inc. today announced that it will participate in two upcoming investor conferences.

23andMe Holding Co., a leading genetic health and biopharmaceutical company, launched Health Action Plan, a new digital tool for 23andMe+ members that draws on results from genetic reports, health history survey data, as well as blood and biomarker data to provide a uniquely tailored set of health recommendations out of hundreds of options.